ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS
申请人:Kasibhatla Rao Srinivas
公开号:US20060223797A1
公开(公告)日:2006-10-05
Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R
12
is a hydroxylated alkyl group and R
9
contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.
[EN] HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS<br/>[FR] COMPOSÉS ANTI-HYPERCHOLESTÉROLÉMIQUE À SUBSTITUTION HÉTÉROCYCLYLE
申请人:MERCK & CO INC
公开号:WO2008057336A2
公开(公告)日:2008-05-15
[EN] This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events. [FR] L'invention concerne des inhibiteurs de l'absorption du cholestérol de formule I : et ses sels pharmaceutiquement acceptables, R12 représentant un groupement alkyle hydroxylé et R9 contenant un cycle hétérocyclique. Les composés sont utiles pour l'abaissement des niveaux de cholestérol, notamment de cholestérol LDL, et pour le traitement de l'athérosclérose et la prévention des évènements athérosclérotiques.
[EN] PROCESS FOR PREPARING AN ANTI-HYPERCHOLESTEROLEMIC COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ ANTI-HYPERCHOLESTÉROLÉMIANT
申请人:MERCK & CO INC
公开号:WO2009054887A1
公开(公告)日:2009-04-30
The present invention relates to a process for preparing inhibitors of cholesterol absorption of Formula II: II and the pharmaceutically acceptable salts and esters thereof, employing a metal-catalyzed dynamic kinetic resolution (DKR) asymmetric transfer hydrogenation (ATH) reaction of racemic acyclic ß-ketoamide bearing a-substituted aliphatic side chain (Intermediate A) and subsequent cyclization of the resulting b-hydroxyamide product (Intermediate B), followed by a synthesis involving two consecutive cross-coupling reactions.